Drug
CB-839 clinical trials
Also written CB-839 and telaglenastat.
- studies test it
- 16
- open now
- 2
- in phase 3
- 0
- first study started
- 2014
Keep track of what changes. Save the CB-839 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
- CBd
- 1
Studies by the year they started
16 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 5
Calithera Biosciences, Inc (11) · David Bajor, MD (1) · M.D. Anderson Cancer Center (1) · Chan, Stephen, MD, PhD (1) · Washington University School of Medicine (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Talazoparib (2) · Capecitabine (1) · Azacitidine (1) · Paclitaxel (1) · Cannabidiol (1) · Dexamethasone (1) · Nivolumab (1)
Studies
Open first, then newest update. How each study uses CB-839 is read from its arms, and is right about nine times in ten.
Testing it · 16
- TEPH: Telaglenastat Efficacy in Pulmonary HypertensionNot yet recruitingPhase 1/2Chan, Stephen, MD, PhDNCT07223528Written as Telaglenastat
- Glutaminase Inhibition and Chemoradiation in Advanced Cervical CancerNot yet recruitingPhase 2Washington University School of MedicineNCT05521997Written as Telaglenastat
- Telaglenastat + Talazoparib In Prostate CancerWithdrawnPhase 2Massachusetts General HospitalNCT04824937Written as Telaglenastat
- CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal CancerCompletedPhase 1/2David Bajor, MDNCT02861300Written as CB-839
- Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromeCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03047993Written as Glutaminase Inhibitor CB-839
- CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaCompletedPhase 2Calithera Biosciences, IncNCT03428217Written as CB-839
- Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 1/2Calithera Biosciences, IncNCT02771626Written as CB-839
- Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)CompletedPhase 2Calithera Biosciences, IncNCT03057600Written as CB-839
- KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCTerminatedPhase 2Calithera Biosciences, IncNCT04265534Written as Telaglenastat
- A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid TumorsCompletedPhase 1/2Calithera Biosciences, IncNCT03965845Written as Telaglenestat (CB-839)
- CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)CompletedPhase 2Calithera Biosciences, IncNCT03163667Written as CB-839
- Study of the Glutaminase Inhibitor CB-839 in Solid TumorsCompletedPhase 1Calithera Biosciences, IncNCT02071862Written as CB-839
- Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsTerminatedPhase 1/2Calithera Biosciences, IncNCT03875313Written as CB-839
- Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult SubjectsCompletedPhase 1Calithera Biosciences, IncNCT04607512Written as telaglenastat
- Study of the Glutaminase Inhibitor CB-839 in Hematological TumorsCompletedPhase 1Calithera Biosciences, IncNCT02071888Written as CB-839
- A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy AdultsCompletedPhase 1Calithera Biosciences, IncNCT02944435Written as CB-839 Capsules
Given in every arm · 2 — CB-839 is usual care beside what is tested
- Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy SubjectsCompletedPhase 1Calithera Biosciences, IncNCT04540965Written as Telaglenastat
- Study of the Glutaminase Inhibitor CB-839 in LeukemiaCompletedPhase 1Calithera Biosciences, IncNCT02071927Written as CB-839
Codes
What other systems call CB-839 · ClinicalTrials.gg INT000127
- UNII (FDA) U6CL98GLP4TELAGLENASTATConfirmed FDA, Wikidata
- Wikidata Q27075751CB-839Confirmed FDA, Wikidata
- DrugBank DB15232One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U6CL98GLP4 | TELAGLENASTAT | Confirmed FDA, Wikidata |
| Wikidata | Q27075751 | CB-839 | Confirmed FDA, Wikidata |
| DrugBank | DB15232 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.